A Mab A Case Study In Bioprocess Development //top\\ Jun 2026

Implementation of QbD strategies in the inoculum expansion ... - PMC

Note: The temperature shift on Day 5 from 36.5°C to 33.0°C successfully prolonged cell viability, shifting the culture from a growth phase to a highly productive stationary phase.

The molecule in this case study is , an IgG1 therapeutic antibody aimed at oncology indications. Target Product Profile (TPP) Indication: Solid tumor oncology. Mechanism of Action: Targeted receptor antagonism. A Mab A Case Study In Bioprocess Development

Maintained high yields while eliminating 99% of host-cell proteins. Shortened Timeline:

If upstream is about growing the protein, downstream is about catching it and cleaning it. This is often the most expensive phase of production due to the high cost of resins and chromatography columns. Implementation of QbD strategies in the inoculum expansion

A mAb: A Case Study in Bioprocess Development Executive Summary

The development of a biologic is a game of trade-offs. The case study of mAb-X highlights three universal truths in bioprocess development: Shortened Timeline: If upstream is about growing the

High-throughput screening was performed using automated micro-bioreactors. Clone CHO-101-C4 was selected based on its specific growth rate, high specific productivity ( ), and favorable glycan profile. Media Optimization

The outcome was a robust run, where the culture achieved a final titer of 4.5 g/L —a benchmark that makes the manufacturing economically viable.

The primary objective of the A-Mab case study is to illustrate the implementation of , ICH Q9 (Quality Risk Management) , and ICH Q10 (Pharmaceutical Quality Systems) guidelines within the biotechnology industry. Traditional bioprocessing historically relied on the philosophy that "the process defines the product". QbD reverses this mindset. It dictates that product requirements define the process.